{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.2","upperLimit":"95.8","value":"87.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Evaluate the overall response rate of patients receiving therapy. Patients are considered as having a response if their overall response is Partial Response or better (CR+sCR+VGPR+PR). The percentage of patients achieving this and the exact 95% confidence interval will be calculated. Responses will be defined using the response criteria determined by the International Working Group for Multiple Myeloma (CR= Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% plasma cells in bone marrow; sCR=CR as defined above plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunoflurorescence; VGPR=Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component\\<100 mg per 24 h; PR=\\>=50% reduction of serum M-protein and reduction in 24-h urinary M-protein by \\>=90% or to \\<200mg per 24 h).","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 150 mg given daily day -7 to day +2","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"All Phase II patients who received at least one dose of study drug and had at least one evaluable post-baseline visit","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Phase II: Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}